2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Andrew L. Pecora, MD, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, discusses the CPIT001 study for patients with hematologic malignancies.
Andrew L. Pecora, MD, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, discusses the CPIT001 study for patients with hematologic malignancies.
The CPIT001 trial is investigating the safety and efficacy of the combination of ipilimumab (Yervoy) and nivolumab (Opdivo) following autologous stem cell transplant in patients with high-risk hematologic malignancies. The first 29 patients enrolled experienced adverse events but those were not unexpected, says Percora.
Related Content: